Related Experiment Video

Updated: Aug 19, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Small molecule epidermal growth factor receptor tyrosine kinase inhibitors: an overview

N Normanno1, M R Maiello, M Mancino

  • 1Department of Experimental Oncology, Istituto Nazionale Tumori-Fondazione Pascale, Naples, Italy. nicnorm@yahoo.com

Journal of Chemotherapy (Florence, Italy)
|February 4, 2005
PubMed

Insights

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) show promise for treating solid tumors. This review covers phase II trial results and discusses mechanisms of tumor cell sensitivity and resistance to these targeted therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) is a key target in solid tumor treatment due to its role in cancer cell proliferation and survival.
  • High EGFR expression correlates with poor prognosis in various cancers.
  • EGFR tyrosine kinase inhibitors (EGFR-TKIs) represent advanced targeted therapies in clinical development.

Purpose of the Study:

  • To review the outcomes of phase II monotherapy trials involving EGFR-TKIs in cancer patients.
  • To explore the molecular mechanisms underlying tumor cell sensitivity and resistance to EGFR-TKIs.

Main Methods:

  • Systematic review of published phase II clinical trial data for EGFR-TKIs as monotherapy.
  • Analysis of preclinical and clinical studies investigating EGFR-TKI resistance mechanisms.

Main Results:

  • Summary of efficacy and safety data from monotherapy trials of various EGFR-TKIs.
  • Discussion of identified molecular pathways influencing response and non-response to EGFR-TKIs.

Conclusions:

  • EGFR-TKIs are a significant therapeutic strategy for solid tumors, with varying efficacy based on tumor type and patient selection.
  • Understanding resistance mechanisms is crucial for optimizing EGFR-TKI treatment strategies and developing next-generation inhibitors.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...